MGF
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Mechano Growth Factor (MGF), known scientifically as IGF-1Ec, is a splice variant of the insulin-like growth factor 1 (IGF-1) gene. Rather than being produced primarily by the liver like the main circulating form of IGF-1, MGF is expressed locally within muscle and other tissues in response to mechanical stress, exercise, or damage.
It is most often discussed in the context of muscle repair and recovery, where researchers have studied its apparent role in activating the satellite (progenitor) cells that help regenerate damaged muscle fibers.
Most of the available evidence comes from cell-culture and animal studies, and results have been mixed. MGF is not approved by any major regulator for human use, and the research literature on it remains limited and at times conflicting.
How it works
In preclinical models, MGF has been studied for its distinct C-terminal E-peptide, the portion that sets it apart from other IGF-1 isoforms. This region is thought to act on muscle progenitor cells, and some studies report that it increases their number and their capacity to fuse into new muscle tissue after mechanical loading or injury.
Because it is expressed transiently and locally, MGF is commonly described as an early-response factor in the repair process. Importantly, not all studies agree: some report clear effects on progenitor cells while others find little or no measurable impact, so the mechanism in humans is not established.
Reported benefits
- Activation of muscle satellite/progenitor cells after mechanical stress (preclinical data)
- Support for muscle repair and regeneration following injury
- Studied for effects on motoneuron survival and muscle strength in disease models
These are reported and studied effects from largely preclinical work, not guaranteed outcomes.
Considerations & side effects
Human clinical data on MGF is very limited, so its safety profile is not well characterized. Alongside promising findings, parts of the literature report no apparent effect on muscle cells, which underscores how emerging and uncertain the evidence remains.
As a growth-factor-related peptide, it warrants particular caution, and product purity varies widely in the research-chemical market. It is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is MGF?
Mechano Growth Factor (MGF), also called IGF-1Ec, is a splice variant of the insulin-like growth factor 1 (IGF-1) gene that muscle tissue produces transiently in response to mechanical stress or damage. It has a unique C-terminal peptide not found in the main liver form of IGF-1.
Is MGF FDA-approved?
No. MGF is not approved by the FDA or any major regulator for human therapeutic use, and is sold for research purposes only.
How does MGF differ from IGF-1?
MGF is one of several splice variants of the same IGF-1 gene. It carries a distinct C-terminal E-peptide and is expressed locally after mechanical loading, whereas the dominant systemic form (IGF-1Ea) is produced mainly by the liver.
Is MGF the same as PEG-MGF?
No. PEG-MGF is a pegylated version engineered for a longer duration of action. Native MGF is non-pegylated and is reported to be very short-acting.
References
- Philippou A, et al. Insulin-Like Growth Factor I (IGF-1) Ec/Mechano Growth Factor — a splice variant of IGF-1 within the growth plate. ↗
- Ates K, et al. The IGF-I splice variant MGF increases progenitor cells in ALS, dystrophic, and normal muscle. ↗
- Riddoch-Contreras J, et al. Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice. ↗
Related compounds
Potent growth hormone releasing peptide. Produces strong GH pulse but may desensitize with prolonged use. Commonly cycled on and off.
Recombinant human growth hormone. Used for GH deficiency, anti-aging, and body composition optimization. Requires careful dosing and monitoring via bloodwork.
A truncated IGF-1 analog (Des(1-3) IGF-1) lacking the N-terminal tripeptide, which sharply reduces IGF-binding-protein sequestration and gives strong, localized anabolic activity. Its very short half-life leads users to inject it near the target muscle post-workout.